Amir Monfaredan

Amir Monfaredan

Auto-generated profile, based on publicly available information

Amir Monfaredan

Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2024 in Russian Open Medical Journal
Verified
Journal Article
Closed access
AMAmir Monfaredan
Amir Monfaredan
FRFakher Rahim
Fakher Rahim
GTGholamreza Tavoosidana
Gholamreza Tavoosidana
MMMohammad Hossein Modarressi
Mohammad Hossein Modarressi
ANalavieh sadat hosseini nasab
alavieh sadat hosseini nasab
EMElahe Motevaseli
Elahe Motevaseli
Background and Aims — Exosomes, which are tiny double-layered membranes originating from eukaryotic cells, have been recognized as a valuable natural vehicle for delivering substances because of their optimal size, compatibility with living organisms, strong structure, ability to carry a large amount of cargo, and capacity to be modified on their surface. Methods — Various strategies have been employed to isolate exosomes due to the challenges associated with maintaining their high purity. The current investigation utilized a soft lithography technique to fabricate channels for exosome separation, incorporating immunoaffinity capabilities. Both biochemical and biophysical assays were conducted to assess the quality of isolated exosomes from various sources (serum, cell supernatant, and urine) and compared with a commercially available kit. Results — The current investigation employed a microfluidic method to capture CD63-conjugated magnetic beads, resulting in a very effective separation of exosomes. Based on the data, there were no notable variations in miRNAs that were statistically significant. This demonstrates that the engineered chip successfully achieved the separation of the exosome while preserving the integrity of its nucleic acid components. Conclusion — The results shown that the current methodology effectively isolated exosomes with a high yield rate, purity, and minimal time requirement. The imatinib laden exosomes demonstrated anticancer efficacy against the KYO-1 cell line in all of their forms.